Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942085 | 1.00 | DRD2 (0.46) | DRD2MAOBKDM1AHPGDDRD3 | |
| SCHEMBL942084 | 1.00 | DRD2 (0.46) | DRD2MAOBKDM1AHPGDDRD3 | |
| SCHEMBL965092 | 0.93 | DRD2 (0.44) | DRD2MAOBKDM1AHPGDDRD3 | |
| SCHEMBL6642035 | 0.93 | DRD2 (0.44) | DRD2MAOBKDM1AHPGDDRD3 | |
| SCHEMBL25318818 | 0.93 | DRD2 (0.44) | DRD2MAOBKDM1AHPGDDRD3 | |
| SCHEMBL28410550 | 0.90 | DRD2 (0.47) | DRD2MAOBKDM1AHPGDDRD3 | |
| SCHEMBL27228950 | 0.89 | MAOB (0.43) | DRD2MAOBKDM1AHPGDKMT2A | |
| SCHEMBL27232496 | 0.89 | MAOB (0.43) | DRD2MAOBKDM1AHPGDKMT2A | |
| SCHEMBL8066651 | 0.87 | DRD2 (0.54) | DRD2MAOBKDM1ADRD3ACACB | |
| SCHEMBL25322196 | 0.87 | BTK (0.47) | DRD2MAOBKDM1AKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015011252-A1 | PYRIMIDINE-PYRIDINONE SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| US-8193206-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-05 | — | — | US | disclosed |
| US-7589197-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY (TW) | 2009-09-15 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TYMS, TYMP, HPRT1 | DRD2 3922/4885MAOB 987/4885KDM1A 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.